This glycoprotein, which is expressed in a wide variety of cell types, often shows increased expression in certain cancers including melanoma, colorectal, prostate, breast, ovarian, bladder, and esophageal cancer suggesting that CD166 is under restricting regulation during carcinogenesis (Davies and Jiang, 2010; Levin et al., 2010; Xiao et al., 2017). This evidence concerns the gene ALCAM and esophageal cancer.